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Abstract
Individuals with Lynch syndrome (LS), one of the most common inherited cancer
syndromes, are at increased risk of developing malignancies, in particular colorectal
cancer (CRC). Regular colonoscopy with polypectomy is recommended to reduce
CRC risk in LS individuals. However, recent independent studies demonstrated that a
substantial proportion of LS individuals develop CRC despite regular colonoscopy.
The reasons for this surprising observation confirmed by large prospective studies
are a matter of debate. In this review, we collect existing evidence from clinical, epi-
demiological and molecular studies and interpret them with regard to the origins and
progression of LS-associated CRC. Alongside with hypotheses addressing colonos-
copy quality and pace of progression from adenoma to cancer, we discuss the role of
alternative precursors and immune system in LS-associated CRC. We also identify
gaps in current knowledge and make suggestions for future studies aiming at
improved CRC prevention for LS individuals.
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1 | NATURAL HISTORY OF LYNCH
SYNDROME-ASSOCIATED COLORECTAL
CANCER
The most common inherited colorectal cancer syndrome, Lynch
syndrome (LS), is caused by inherited pathogenic germline variants of
DNA mismatch repair (MMR) genes responsible for correction of mis-
matches during DNA replication: MLH1, MSH2, MSH6 and PMS2.1 In
addition, deletions involving the EPCAM gene may silence the adja-
cent MSH2 gene. The prevalence of pathogenic MMR gene variants
predisposing to LS in the general population is estimated to be 1:250
or even higher.2-5 LS is inherited as an autosomal-dominant trait,
meaning that carriers of a monoallelic pathogenic germline variant
(insight-database.org6), hereafter referred to as “carriers” or “MLH1/
MSH2/MSH6/PMS2 carriers”, have an increased lifetime cancer risk.
However, for LS-associated cancers to develop, somatic second hits
that inactivate the remaining functional MMR allele are required (con-
sistent with Knudson's two-hit hypothesis).7,8 As a consequence of
MMR deficiency, mismatch mutations can accumulate resulting in
hypermutated tumors with >10point mutations per megabase.9 MMR
deficiency also leads to the accumulation of insertion/deletion of
mutations at short repetitive sequences (microsatellites), as polymer-
aseslippage-induced insertion/deletion loops are not repaired during
DNA replication, and the mutation is passed on to subsequent cell
generations.10 Insertion/deletion of mutations alter the length of
microsatellites, resulting in the genetic phenotype of microsatellite
instability (MSI).
Microsatellite mutations residing in protein-encoding regions of
the genome can lead to loss of function of tumor suppressor genes,
thereby contributing to cancer development and also to the genera-
tion of frameshift peptide (FSP) neoantigens. Certain MSI-related FSP
neoantigens can encompass neoepitopes completely unknown to the
host's immune system. This mechanism is commonly considered to be
responsible for the high immunogenicity of MSI tumors11 that has
been demonstrated by several studies showing dense local immune
infiltration12-14 and reactivity of these immune cells to FSPs.15,16 The
immunogenicity of MSI tumors is also a likely reason for the observed
favorable prognosis of MSI cancers and their response to immune
checkpoint blockade therapy.14,17-19
The most common clinical manifestations of LS are colorectal can-
cer (CRC) and endometrial cancer. Prior to the discovery of LS-causing
MMR gene variants in the early 1990s, namely those affecting MSH2
2 AHADOVA ET AL.
and MLH1, 20-22 the syndrome had been termed hereditary non-
polyposis colorectal cancer (HNPCC) syndrome.23 HNPCC defined
the high CRC risk and underlined the major phenotypic difference
between the syndrome and familial adenomatous polyposis (FAP):
FAP presents with hundreds to thousands of colonic adenomatous
polyps, while the number of polyps in LS patients is not substantially
changed in comparison to the general population.24-26 Even though
polyposis is not part of the LS phenotype, benign polyp precursor
lesions of LS CRC have been detected.27,28 This suggested that polyp
removal may be an effective measure for CRC prevention in LS and
led to international clinical guidelines recommending regular colonos-
copy in LS patients.
2 | PERFORMANCE OF COLONOSCOPY
FOR CRC PREVENTION IN THE GENERAL
POPULATION AND IN LS
In the general population, colonoscopy with polypectomy has been
associated with a reduction in CRC risk and improved survival through
early detection of CRC.29-32 In an observational re-analysis of the
National Polyp Study (US) undertaken in the general population,
screening colonoscopy with polypectomy reduced the risk of CRC
death by 53% in 15 years of follow-up,33 and the incidence of CRC was
reduced by at least 66%. 34 A more recent population-based study
(Germany) by Brenner et al31 reported a 77% risk reduction for CRC in
individuals who had a screening colonoscopy in the 10 years prior to
assessment. Interestingly, and similar to other studies,30,32,35 the risk
reduction by colonoscopy was higher for left-sided CRC (84%) com-
pared to right-sided CRC (56%). The preventive effect of colonoscopy
on right-sided CRC was particularly limited in the younger age group,
with only a 26% risk reduction in patients aged between 50 and
59 years. Although this study did not identify a difference in risk reduc-
tion between patients with and without a family history of CRC, the
limited efficacy of colonoscopy particularly in young patients and for
the right-sided colon is intriguing.36,37 It may in part relate to more
limited efficacy of colonoscopy to prevent CRC in LS, a disease
predisposition known to be associated with an increased proportion of
right-sided CRCs and earlier onset compared to the general
population.38
In LS, CRC risk and its reduction by colonoscopy surveillance have
been analyzed by several studies with different designs. Retrospective
studies largely covering the time period before the introduction of
regular colonoscopy reported up to 78% “natural” (without surveil-
lance) risk of developing CRC in individuals with HNPCC.39,40 A land-
mark non-randomized controlled study by Jarvinen et al41 reported
halving of CRC risk by 3-yearly colonoscopy in HNPCC, including a
group of proven MMR carriers. However, LS patients under regular
colonoscopy still had up to 15% risk of developing CRC in
10 years.41-49 A summary of studies assessing CRC risk in LS carriers
under surveillance independent of the affected MMR gene is pres-
ented in Table 1. Differences in the CRC risk observed between the
studies can be explained by the variations in study design (retrospec-
tive vs prospective), colonoscopy protocols, eligibility criteria and cen-
soring strategies.
In line with these observations, the Prospective Lynch Syndrome
Database (PLSD, plsd.eu), the largest prospective database of known
MMR carriers, demonstrated the development of a substantial num-
ber of CRCs despite colonoscopy with polypectomy.50 Even in LS
patients undergoing regular colonoscopy surveillance, CRC was the
most frequent first cancer observed,51 becoming clinically manifest as
“incident cancers” (ie, diagnosed after the beginning of surveillance
period). These findings were confirmed in an independent large series
of MMR carriers.52 In between-country comparisons, point estimates
of the incidence of CRC in MLH1 carriers who underwent colonos-
copy every 1 or 2 years were insignificantly higher53 or similar54 to
those receiving colonoscopy only every 3 to 3.5 years. Neither stage
of CRC54,55 nor survival56 after diagnosis of CRC were associated
with time since last colonoscopy. Notably, adjusting for country of ori-
gin to minimize a potential influence of country-specific factors did
not change the results.54 Previous studies also did not detect a signifi-
cant variant-specific influence on penetrance of LS,57 indicating that a
potential effect of founder mutations58 on the observed correlations
is minor at most.53 These observations support the concept that
TABLE 1 CRC risk under surveillance in LS variant carriers independent of the affected MMR gene
Study Setting Colonoscopy interval (years) Observation time CRC incidence
Jarvinen et al 41 Prospective 3 15 years 18%
De vos tot Nederveen Cappel et al 44 Retrospective 2 to 3 10 years 10.5% (95% CI: 3.8-17.2)
Mecklin et al 42 Prospective 2 to 3 Age 60 Men: 35% (95% CI: 16%-49%)
Women: 22% (95% CI: 7%-34%)
Järvinen et al 45 Prospective 2 to 3 11.5 years 12.4%
Stupart et al 46 Prospective 1 to 2 5 years 11%
Engel et al 47 Prospective 1 to 2 Age 60 23% (95% CI: 14.8%-31.2%)
Vasen et al 48 Retrospective 1 to 2 10 years 6% (95% CI: 2.7%-8.7%)
Newton et al 49 Retrospective 2 Age 70 25% (95% CI: 17-32%)
Engel et al 54 Prospective 1 to 3 10 years 8.4% (95% CI: 7.1%-10.2%)
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reducing colonoscopy intervals below 2 years is generally not associ-
ated with a clinical benefit in LS.
Moreover, LS carriers with a history of previous CRC and hemi-
colectomy, or with a history of previous extracolonic cancer, present
with a similarly high CRC risk as LS carriers without previous history
of cancer.59 Therefore, the option of more radical surgery at first CRC
should be discussed with patients; alternatively, stringent surveillance
measures for controlling CRC risk in LS patients have to be maintained
also after first cancer diagnosis.60-64
Importantly, CRC risk and colonoscopy efficacy depend on the
affected MMR gene: MLH1 and MSH2 carriers had a lifetime CRC risk
of up to 50%,57,65,66 which remained high despite regular colonoscopy
surveillance.52,57 On the other hand, MSH6 65,66 and PMS2 67 carriers
had a substantially lower lifetime CRC risk, which might be further
reduced by colonoscopy surveillance in MSH6 carriers or even
become unmeasurably low in PMS2 carriers52,57,68 (Table 2, Figure 1).
Difference in the protection against CRC afforded by colonos-
copy in the general population compared to LS suggests that any bio-
logical differences between LS and sporadic CRC in the general
population maybe important determinants of the success of colonos-
copy in cancer prevention in these two settings. In recent years, sev-
eral hypotheses have been proposed to explain the observed
epidemiologic data.55,69 We discuss current hypotheses and consider
the most likely explanations for the reported observations.
3 | HYPOTHESES EXPLAINING CRC
DESPITE SURVEILLANCE IN LS
3.1 | “Missed” lesions
One hypothesis to explain the occurrence of incident CRC in LS
patients under colonoscopic surveillance is failure to identify or suc-
cessfully remove adenomas. According to this hypothesis, improving
the quality of colonoscopy would lead to improved detection and
removal of adenomas and reduce incident cancers (Figure 2, “missed
lesions”). The claim is that if colonoscopy is of high quality, all/most
CRC in LS may be prevented.
Several factors impacting colonoscopy quality should be consid-
ered, including time-trends in techniques used, knowledge of what to
look for, and inter-observer and intra-observer reproducibility. An
incomplete colonoscopy that does not reach the caecum, inadequate
bowel preparation, an inexperienced examiner, short withdrawal time
TABLE 2 Cumulative CRC risk in confirmed LS variant carriers depending on the affected MMR gene reported by the largest studies
published in the last decade
Study Surveillancea Gender
Cumulative colorectal cancer risk at the age of 70b (95% CI)
MLH1 MSH2 MSH6 PMS2
Bonadona et al 66 No Both 41% (25%-70%) 48% (30%-77%) 12% (8%-22%) n.a.
Dowty et al 57 No Male 34% (25%-50%) 47% (36%-60%) n.a. n.a.
Female 36% (25%-51%) 37% (27%-50%)
Broeke et al 67 No Male n.a.c n.a. n.a. 13% (8%-22%)
Female 12% (7%-21%)
Dominguez-Valentin et al 52 Yes Male 53% (45%-62%) 46% (37%-59%) 12% (5%-35%) 3% (1%-35%)
Female 44% (37%-52%) 42% (35%-50%] 20% (12%-41%)
aSurveillance here refers to studies that included data only from patients undergoing regular colonoscopy with polypectomy. Note that the first three stud-
ies are based on often not fully documented retrospective cohorts including patients with differing colonoscopy exposures and censoring at the time of
first colonoscopy or first polypectomy.
bAll studies reported the cumulative CRC risk at the age of 70 years, except for Broeke et al that reported the cumulative CRC risk at the age of 80.
cn.a. not analyzed.
F IGURE 1 Schematic illustration of the effect of surveillance on
CRC risk for different MMR gene variant carriers (based on the data
summarized in Table 2). The CRC incidence is reduced by
colonoscopy in PMS2 carriers, and might be reduced by colonoscopy
in MSH6 carriers, whereas in MLH1 and MSH2 carriers CRC incidence
seems not to be substantially influenced by colonoscopy surveillance.
The darker shades represent the range of average risks reported by
different studies for males and females, whereas the brighter shades
represent the range of reported confidence intervals. Note: Influence
of different penetrance in carriers of variant in different MMR genes
on the colonoscopy efficacy cannot be formally excluded
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and the use of chromoendoscopy represent factors that may affect
the likelihood of detecting polyps. In particular, small polyps or non-
pedunculated flat lesions characteristic for LS may be overlooked.70,71
A recent systematic review and meta-analysis demonstrated an ade-
noma miss rate as high as 33% in patients at increased CRC risk.71
However, the majority of the studies conducted have not reported
detailed quality measures for colonoscopy.71,72
Due to the wide acceptance of the adenoma-carcinoma model,
adenomas removed have been often used as surrogate marker for
CRCs prevented. One attempt to standardize colonoscopy quality
across centers is the definition of the “adenoma detection rate”
(ADR), describing the proportion of colonoscopies that result in the
detection of an adenoma. In fact, ADR has been shown to inversely
correlate with the risk of incident cancer.73,74 However, using ADR
for assessing surveillance quality in LS setting with regular exami-
nations evidently has limitations, as population characteristics,
namely the growth dynamics of adenomas in a given population,
directly affect ADR. Accordingly, the highest possible and the low-
est recommendable ADR for current LS surveillance colonoscopies
are unknown and may depend on the distribution of pathogenic
variants in the cohort, the extent of previous colectomies and the
frequency of carriers ascertained without previous CRC. ADRs so
far reported by independent studies vary: one large study that
pooled prospective surveillance data from three different countries
showed an average ADR of 16% per examination,54 but ADR
values as low as 10.6% and as high as 52.5% have been reported
both before and after the implementation of a quality-
improvement program.73,75-79 A universal ADR cannot be deter-
mined due to geographical differences in adenoma risk as well as
different target populations used to determine the ADR. Another
important limitation of the ADR as a marker for high-quality colo-
noscopy is lack of information on the completeness of adenoma
resection, as detected adenomas, when not completely resected,
may also lead to incident cancer development.80
There is evidence that more sophisticated endoscopic modalities
could lead to more efficient detection of adenomatous lesions during
LS surveillance colonoscopy.72,78,81-83 For example, it has been shown
that chromoendoscopy, virtual chromoendoscopy (I-SCAN) and nar-
row-band imaging approaches allow detection of significantly more
adenomas compared to standard colonoscopy.78,81-83 A recent study
reporting an optimized colonoscopy surveillance program suggested
improvements in the cancer detection rate in LS without altering the
ADR.75 Another randomized controlled study analyzing neoplasia
detection rates in LS at baseline and follow-up colonoscopy did not
find a significant added value for chromoendoscopy over high-definition
white-light endoscopy for the proximal colon,77 nor did a randomized
non-inferiority study comparing these two techniques for LS surveil-
lance.84 However, a clear time-trend toward higher ADR after the
introduction of high-definition endoscopy has been observed by a
recent study, also reporting development of incident cancers after the
high-quality penultimate colonoscopy.85
Currently, it is not known how much optimization of
colonoscopy—relating to all of the factors affecting colonoscopy qual-
ity discussed earlier—would reduce the occurrence of CRC in
LS. Randomized controlled trials analyzing the impact of novel sensi-
tive endoscopy techniques, including those using artificial intelli-
gence-based approaches, on the ADR and on cancer incidence in LS
are needed to clarify and quantify the contribution of “missed” lesions
to incident cancers.
The surveillance colonoscopies currently reported in prospective
studies have largely been conducted at highly specialized centers in
different parts of the world. Given their expertise, and their ability to
very effectively prevent CRC in the general population, it seems
unlikely that inter-observer differences or technical limitations could
be the only explanations for the high proportion of LS patients devel-
oping incident cancer while under regular colonoscopy surveillance.
Although optimization of colonoscopy may reduce occurrence of CRC
in LS, the extent of cancer prevention needs to be quantified in
F IGURE 2 Summary of discussed
hypotheses for CRC incidence in LS
despite regular colonoscopy. The figure
schematically summarizes the discussed
hypotheses, including missed lesions, fast
progression, alternative precursors,
disappearing lesions and induced lesions,
showing the hypothetical snapshots of
colon during colonoscopy examination,
of CRC progression/regression in the
time intervals between colonoscopy
examinations and of colon during the
next examination
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prospective, ideally randomized international multicenter studies. To
this end, time-trends will now be analyzed in the PLSD.
3.2 | Fast progression of newly formed adenomas
Another possible explanation for occurrence of CRC in LS carriers
despite colonoscopy surveillance is provided by the hypothesis of
accelerated progression from adenoma to carcinoma. This proposes
that CRCs in LS develop from adenomas, but progression is so fast
that there is often no time to detect and remove the lesion at pre-
cancerous adenoma phase (Figure 2, “fast progression”). Several
observations support this concept. In the general population, CRC
formation usually involves a benign polypoid precursor stage and the
transformation to invasive cancer appears to take 10 years or
more.86 This is why 10-yearly colonoscopy intervals are considered
sufficient to successfully lower the incidence of CRC in the general
population.87,88 In LS, however, the progression to CRC has been
suggested to be accelerated compared to the general popula-
tion.89-92 The different progression times indicate that there are bio-
logical differences between CRC development in LS carriers and the
general population.
A study estimating the polyp dwell time has demonstrated a time
period of approximately 3 years being required for the development
of an advanced lesion, with an equal dwell time to adenoma as to can-
cer formation.93 Calculations of longitudinal parameters, such as pro-
gression time, based on cross-sectional observations have to be
interpreted with caution. However, equal dwell times of adenomas
and cancers could have two possible reasons: either the progression
from adenoma to carcinoma is very fast, or dwell time to adenoma
and dwell time to carcinoma are not always connected by one linear
progression, but rather represent two distinct branches of progression
with different end points.
The hypothesis of accelerated progression is also consistent with
the minor differences in adenoma incidence in LS compared to the
general population.25,26 This finding has been interpreted as
supporting evidence for the hypothesis that elevated CRC risk in LS
patients does not result from an increased likelihood of adenoma
initiation as in FAP, but rather from accelerated progression of
pre-existing adenomas into cancer due to acquisition of MMR
deficiency and an increased mutation rate.89,91,94,95 The hypothesis of
faster progression was further supported by the correlation of MMR
deficiency with larger size and higher grade of adenomas in
LS,25,96-100 though some studies reported high-grade dysplasia and
MSI phenotype in lesions smaller than 5 mm.25
Although it seems highly likely that a subset of LS CRCs follow
the tumorigenesis model proposed by the hypothesis of accelerated
progression, other evidence suggests that many CRCs in LS, perhaps
even the majority, do not. As discussed earlier, application of colonos-
copy surveillance every 3 years has led to halving of the CRC risk and
a reduction in CRC-related mortality; however, further improvement
was not achieved by shortening colonoscopy intervals from 3 years
down to 1 year, as shown by a PLSD study.53 This was also confirmed
by a large prospective observational study of three European LS regis-
tries comparing the outcomes of different surveillance protocols in
three countries and showing no difference in the incidence of CRC
between the three different colonoscopy intervals (annual, 2- and
3-yearly colonoscopy).54 There was also no difference in the stage of
CRCs detected, a finding which was later confirmed by studies of the
PLSD.55 A recent study in the PLSD reported no difference in CRC
survival associated with the time since last colonoscopy prior to CRC
diagnosis.56 In summary, these reports question the assumptions
underlying current clinical guidelines for colonoscopy in carriers: AGA:
1-2-year interval (GRADE low-quality evidence)101; ACG: at least
2-year interval (moderate quality and very low-quality evidence for
annual interval)102; ASCO & ESMO: 1-2 year interval103; ESGE: 2-year
interval (moderate-quality evidence)104; updated guidelines of EHTG
are currently in preparation.
Interestingly, the success of colonoscopic surveillance could
depend on which MMR gene is involved. For example, PMS2 car-
riers undergoing regular colonoscopy have negligible CRC risk,
especially at young ages,52,105 and low CRC risks have also been
shown for MSH6 carriers under surveillance.52,57 Such observations,
further corroborated by distinct molecular characteristics of tumors
from different MMR carriers,106 could point to biological differ-
ences between colorectal tumorigenesis in different genetic back-
grounds: the apparently hard-to-detect cancer precursors present
in MLH1 and MSH2 carriers seem to be absent or very rare in
PMS2 or MSH6 carriers and the general population. These differ-
ences should be considered when formulating guidelines for man-
agement of LS.
3.3 | Not all CRCS in LS develop in a
macroscopically visible adenoma, and not all
adenomas are precursors
In recent years, evidence for colonoscopically invisible precursor
lesions, or alternative, “adenoma-free” progression routes to cancer,
has accumulated. Such routes could start from mismatch repair-
deficient crypt foci (MMR-DCF) that are found in the normal-looking
colonic mucosa of LS carriers but not in sporadic MSI CRC patients
(Figure 2, “other precursors”).107,108 These lesions are not only
undetectable by colonoscopy, but also microscopically unidentifiable,
unless MMR protein staining is performed.107,108 MMR-DCF
exhibit MSI and carry mutations in microsatellite-bearing genes,
also found in advanced lesions109, suggesting their potential as
cancer precursors.
Molecular analysis of LS CRC in fact indicates that MMR defi-
ciency is often an early or even initiating event,110,111 which fre-
quently precedes canonical mutations affecting the genes APC and
KRAS.112 Moreover, it has been demonstrated that a substantial pro-
portion of LS-associated CRC may develop without an adenomatous
phase: LS CRCs that did not display features of cancer-adjacent ade-
noma cells were associated with specific molecular alterations, mainly
CTNNB1 and TP53 mutations.96,99 This observation indicates the
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possibility that alternative molecular progression events, similar to
inflammatory bowel disease (IBD)-associated colorectal neoplasia that
are commonly initiated by APC-independent events,113,114 are associ-
ated with the lack of polypoid precursor lesions.115 This pathway of
progression seems to be less common in PMS2-associated CRC, an
observation that may reflect the minimal risk of cancers in PMS2 car-
riers under surveillance.116
Thus, existing data strongly suggest that the assumption of a
sequential model of colorectal carcinogenesis in LS where CRC is
always preceded by an adenoma is wrong or, at least, a considerable
oversimplification.117,118 Thus, accounting for the diversity of colorec-
tal carcinogenesis suggested by Jeremy Jass,117,118 it is important to
acknowledge the heterogeneity of LS CRCs. Instead of seeking one
model for all cases, at least three pathways should be considered:
(a) progression from an adenoma with secondary inactivation of the
MMR system, (b) progression from an initially MMR-deficient ade-
noma and (c) progression from MMR-DCF directly to invasive cancer
without adenoma formation.110
If there is more than one pathway to CRC in LS, what is the rela-
tive contribution of each? This question is difficult to answer pre-
cisely. Importantly, LS carcinogenesis might be influenced by the
“observation” itself having an effect on the observed data. Here, the
process of observation, that is, colonoscopy, may affect the disease
status, either because the relative contributions of the three pathways
are changed by removing adenomas, or because of the colonoscopy-
mediated effects influencing carcinogenesis (as discussed later). The
results reported by PLSD, in which cancers continued to develop
despite colonoscopy, may reflect the effect of colonoscopy blocking
progression from adenomas as precursors, and thereby increasing the
proportion of CRCs progressing through a different molecular path-
way, potentially similar to nonpolypoid CRCs in IBD patients,115 via
direct invasive growth without a polypoid precursor. Notably, molecu-
lar evidence from CRCs suggest that the proportion of cancers pro-
gressing through the second and the third, MMR deficiency-initiated
pathways outweigh the proportion of cancers progressing through
the first, adenoma-initiated pathway in LS.110
This conclusion has wide-ranging implications. First, it explains why
even high-quality, short-interval colonoscopy with meticulous inspec-
tion of the intestinal mucosa and removal of all polyps cannot
completely prevent LS-associated CRC, as CRC may develop without
ever passing through a detectable non-invasive phase. Second, it pre-
dicts that any approach targeting MMR-deficient cells should be very
effective in preventing the majority of LS-associated CRCs, particularly
non-polypous cancers. Third, studies assessing CRC development in LS
need to account for colonoscopy surveillance as a factor in the
populations studied. Fourth, a better understanding of non-adenoma
precursors is needed to define suitable end points for prevention trials
and improve prevention and surveillance strategies. This is underlined
by the observation of the CAPP2 study that, similar to observations in
the general population,119 reported a significant reduction in incidence
of CRC, but not of colorectal adenomas, upon regular aspirin use.120
Conceptually, the hypothesis of invisible lesions is very similar to
the hypothesis of missed lesions, with one very important difference:
the hypothesis of missed lesions assumes that an improvement of
colonoscopy techniques, shorter surveillance intervals or better train-
ing of gastroenterologists will make the invisible visible, at a phase of
pre-invasive tumor development. Whether this is true and to what
extent, remains to be demonstrated in prospective studies.
4 | HYPOTHESES ADDRESSING THE
HIGHER CRC INCIDENCE OBSERVED WITH
MORE FREQUENT COLONOSCOPY
SURVEILLANCE
4.1 | Overdiagnosis and disappearing lesions
The trend toward higher CRC incidence in groups of LS patients sub-
jected to colonoscopy with shorter intervals53 is surprising and could
be explained by the spontaneous disappearance of colonic lesions.
This is theoretically possible for precancerous lesions or even for
invasive cancers (Figure 2, “disappearing lesions”).55 If true, longer
colonoscopy intervals may tend to result in fewer identified lesions,
because one has to look frequently to catch lesions destined to dis-
appear between colonoscopies. Shortening of the colonoscopy inter-
val could lead to detection of lesions that otherwise would have
been eliminated by patient's immune system. Biological support for
this hypothesis comes from data on MMR-DCF prevalence and LS
penetrance: the number of MMR-DCF per LS patient is estimated to
be 1000 times or more the numbers of manifest cancers.107 On the
one hand, such a low progression rate might be explained by acquisi-
tion of growth-repressing mutations leading to apoptosis or onco-
genic mutations leading to oncogene-induced senescence of MMR-
DCF; on the other hand, immune responses against these lesions
could contribute to their elimination. It is known that LS-associated
cancers are highly immunogenic, as shown by dense immune infiltra-
tion and Crohn's-like reactions observed in these tumors,12,14 as well
as their response to immune checkpoint blockade therapy.16,19
LS-associated CRCs, as well as MMR-DCFs, have been shown to
carry coding microsatellite mutations, resulting in the generation of
FSPs that can elicit strong immune responses and cause in vitro kill-
ing of FSP-expressing cells by T cells.121 Moreover, systemic cellular
immune responses to FSP have been found in the blood of healthy
LS carriers,15 suggesting that FSP neoantigen-specific T cells may
eliminate MMR-deficient lesions that might include both MMR-
DCFs and more advanced lesions. Indeed, it has been shown that
adenomas can regress,122-124 and even cancers can be attacked by
immune responses of the host and should be particularly vulnerable
in LS due to a high tumor mutational burden and tumor-associated
antigen load.125-128 The low probability of lymph node and distant
metastases and the good prognosis of LS-related CRC may also
reflect the immune system's capability to restrain CRC.
It would be interesting to monitor the progression rate of adeno-
mas in LS over time; however, due to ethical considerations such a
study could not reasonably be conducted in humans. Recently devel-
oped organoid models may facilitate research into carcinogenetic
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cascades in multiple organs. The favorable culture time and ability to
retain genetic stability over time of such models may help to circum-
vent the complexity of in vivo studies of adenomas, carcinomas and
immune response in humans.129
In short, the probability for developing a malignancy may be
described as a balance between the carcinogenic mechanisms produc-
ing CRCs and the host's immune system removing them.
Alternatively, higher CRC incidence upon shorter colonoscopy
intervals could be explained by the different penetrance of pathogenic
variants in the same MMR gene (eg, strong founder mutation effect in
the Finnish population58). Currently available data do not suggest a
major influence of this factor,53,57 though future studies are
warranted.
4.2 | Induced lesions
The observation of a higher CRC incidence occurring in the context of
shorter colonoscopy intervals is also consistent with colonoscopy
itself playing a role in the pathogenesis of CRC (Figure 2, “induced
lesions”). However, given the success story of colonoscopy in CRC
prevention in the general population, this theoretical possibility seems
unlikely in practice. Despite this, at least two colonoscopy-associated
factors can be proposed that might favor tumor progression under
certain circumstances. First, bowel preparation prior to colonoscopy
affects the microbiome composition of the colon in a persisting
way.130 The impact of certain bacterial species in the development of
CRC through modulation of the immune response has been exten-
sively studied;131-134 and it is conceivable that bowelpreparation-initi-
ated microbiome changes may be related, positively or negatively,
with CRC progression in the individual being examined. It is possible
that such effects, even if minor at the individual level, may become
detectable in a larger population. A second factor linked to the exami-
nation procedure itself is mechanical irritation. In theory, local pres-
sure, distension and abrasion by the endoscope could lead to micro-
injuries of the mucosal surface, particularly if biopsies are taken, dis-
turbing cell–cell contacts and damaging the mucosa. This could lead
to the initiation or acceleration of a malignant process, particularly if
MMR-deficient cells are in the vicinity. A recent study analyzing the
impact of colonoscopy on the development of metachronous CRC has
shown the possibility of tumor seeding during colonoscopy; the risk of
such tumor cell spreading was estimated to be 0.3% to 0.6%.135 How-
ever, the authors are not aware of any further experimental evidence
supporting these theories so far. Therefore, colonoscopy will remain
one central pillar of cancer prevention in LS with a reported risk of
severe complications of, at most, 0.3%.136,137
5 | SUMMARY
CRC incidence in LS remains high despite regular colonoscopy.
Although technical limitations may explain some incident cancers,
strong evidence indicates that multiple CRC precursors in LS follow
distinct fates of persistence, progression or regression depending on
several factors. If we acknowledge these possibilities, we can better
interrogate the biologic diversity and complexity of LS. By designing
clinical trials that produce data analyzable for the distinct pathways
separately, we will learn more about LS carcinogenesis. This knowl-
edge will be essential to refine prevention and treatment strategies
for LS patients.
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